Subrata Kumar Pore (Subrata K Pore)

Pitt ID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 4

Top Topics

Prostate Cancer

Radical Prostatectomy

Intellectual Disability

Top Venues

Molecular cancer therapeutics

Journal of cellular biochemistry

Journal of materials chemistry. B

Institute of Advanced Study in Science and Technology

Indian Institute of Chemical Technology (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Institute of Advanced Study in Science and Technology Jul 01 2019

India

Ramalingaswami Fellow :: Life Science Division

Education History

Indian Institute of Chemical Technology Aug 05 2007 - Jan 31 2014

India

PHD :: Biomaterials group

Indian Institute of Technology Kharagpur Apr 01 2005 - Apr 30 2007

India

MSC :: Chemistry

University of Calcutta Apr 01 2002 - Apr 30 2005

India

BSC :: Chemistry (Honors)

Publications

Anjali Singh, Subrata Kumar Pore, Jayanta Bhattacharyya
Encapsulation of telmisartan inside insulinoma-cell-derived extracellular vesicles outperformed biomimetic nanovesicles in modulating the pancreatic inflammatory microenvironment. Journal of materials chemistry. B (2024)
Krishna B Singh, Eun-Ryeong Hahm, Subrata Kumar Pore, Shivendra V Singh
Leelamine Is a Novel Lipogenesis Inhibitor in Prostate Cancer Cells In Vitro and In Vivo. Molecular cancer therapeutics 18 (10) (2019)
Subrata Kumar Pore, Anirban Ganguly, Samaresh Sau, Sudhakar Godeshala, Anantha K Kanugula, Ramesh Ummanni, Srigiridhar Kotamraju, Rajkumar Banerjee
N-end rule pathway inhibitor sensitizes cancer cells to antineoplastic agents by regulating XIAP and RAD21 protein expression. Journal of cellular biochemistry 121 (1) (2019)
Subrata Kumar Pore, Eun-Ryeong Hahm, Su-Hyeong Kim, Krishna B Singh, Lea Nyiranshuti, Joseph D Latoche, Carolyn J Anderson, Juraj Adamik, Deborah L Galson, Kurt R Weiss, Rebecca J Watters, Boeun Lee, Prashant N Kumta, Shivendra V Singh
A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer-Induced Osteolytic Bone Resorption. Molecular cancer therapeutics 19 (2) (2019)